Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Nils Venhoff, MD

Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg
Freiburg, Germany

Medical education Albert-Ludwigs University
Specialist in Internal Medicine
Specialist in Rheumatology
Specialist in Immunology
Senior Physician Clinic of Rheumatology and Clinical Immunology, Medical Center, University Freiburg

Presentation(s):

  • 1175: Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Chugai: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing), pending patent application on the use of secukinumab in GCA which could provide him financial benefits (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); UCB: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Vifor: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)